The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice

Inflammation

Volumn 39, Issue 1, 2016, Pages 413-424

  Waumans, Yannick ^a   Vliegen, Gwendolyn ^a   Maes, Lynn ^a   Rombouts, Miche ^a   Declerck, Ken ^a   Van Der Veken, Pieter ^a   Vanden Berghe, Wim ^a   De Meyer, Guido R Y ^a   Schrijvers, Dorien ^a   De Meester, Ingrid ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

atherosclerosis; dipeptidyl peptidase; DPP4; macrophages; monocytes

Indexed keywords

DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE 8, MOUSE; DIPEPTIDYL PEPTIDASE 9, MOUSE; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, MOUSE; INTERLEUKIN 6;

ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; BIOSYNTHESIS; C57BL MOUSE; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; FEMALE; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; MACROPHAGE ACTIVATION; METABOLISM; MONOCYTE; MOUSE; SECRETION (PROCESS);

ANIMALS; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL LINE; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; FEMALE; INTERLEUKIN-6; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES;

EID: 84958058029     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-015-0263-5     Document Type: Article

References (53)

1. WHO. 2014. The top 10 causes of death. World Health Organization.
2. Silvestre-Roig, C., M.P. de Winther, C. Weber, M.J. Daemen, E. Lutgens, and O. Soehnlein. 2014. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circulation Research 114: 214–226. doi:10.1161/CIRCRESAHA.114.302355.
3. Stöger, J., M. Gijbels, and S. Van der Velden. 2012. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 225: 461–468.
4. Van der Valk, F., D. Van Wijk, and E. Stroes. 2012. Novel anti-inflammatory strategies in atherosclerosis. Current Opinion in Lipidology 23: 532–539.
5. Drucker, D., and M. Nauck. 2006. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet 368: 1696–1705. doi:10.1016/S0140-6736(06)69705-5.
6. Deacon, C.F. 2011. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity & Metabolism 13: 7–18. doi:10.1111/j.1463-1326.2010.01306.x.
7. Kieffer, T.J., C.H. McIntosh, and R.A. Pederson. 1995. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585–3596. doi:10.1210/endo.136.8.7628397.
8. Drucker, D.J., Q. Shi, A. Crivici, M. Sumner-Smith, W. Tavares, M. Hill, L. DeForest, S. Cooper, and P.L. Brubaker. 1997. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nature Biotechnology 15: 673–677. doi:10.1038/nbt0797-673.
9. Ahmad, S., L. Wang, and P.E. Ward. 1992. Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. The Journal of Pharmacology and Experimental Therapeutics 260: 1257–1261.
10. Brandt, I., A.-M. Lambeir, J.-M. Ketelslegers, M. Vanderheyden, S. Scharpé, and I. De Meester. 2006. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clinical Chemistry 52: 82–87. doi:10.1373/clinchem.2005.057638.
11. Busso, N., N. Wagtmann, C. Herling, V. Chobaz-Péclat, A. Bischof-Delaloye, A. So, and E. Grouzmann. 2005. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. The American Journal of Pathology 166: 433–442. doi:10.1016/S0002-9440(10)62266-3.
12. Broxmeyer, H.E., J. Hoggatt, H. O’Leary, C. Mantel, C. Brahmananda, S. Cooper, S. Messina-Graham, G. Hangoc, S. Farag, S. Rohrabaugh, X. Ou, J. Speth, L. Pelus, E. Srour, and T. Campbell. 2012. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nature Medicine 18: 1786–1796. doi:10.1038/nm.2991.Dipeptidylpeptidase.
13. Marchetti, C., A. Di Carlo, F. Facchiano, C. Senatore, R. De Cristofaro, A. Luzi, M. Federici, M. Romani, M. Napolitano, M.C. Capogrossi, and A. Germani. 2012. High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia 55: 236–244. doi:10.1007/s00125-011-2213-6.
14. Forssmann, U., C. Stoetzer, M. Stephan, C. Kruschinski, T. Skripuletz, J. Schade, A. Schmiedl, R. Pabst, L. Wagner, T. Hoffmann, A. Kehlen, S.E. Escher, W.-G.W.-G. Forssmann, J. Elsner, S. von Hörsten, and S. von Horsten. 2008. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. The Journal of Immunology 181: 1120–1127. doi:10.4049/jimmunol.181.2.1120.
15. Jost, M.M., J. Lamerz, H. Tammen, C. Menzel, I. De Meester, A.-M. Lambeir, K. Augustyns, S. Scharpé, H.D. Zucht, H. Rose, M. Jürgens, P. Schulz-Knappe, and P. Budde. 2009. In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma. Biochemical Pharmacology 77: 228–237. doi:10.1016/j.bcp.2008.09.032.
16. Morimoto, C., and S.F. Schlossman. 1998. The structure and function of CD26 in the T-cell immune response. Immunological Reviews 161: 55–70.
17. Van Goethem, S., V. Matheeussen, J. Joossens, A.-M. Lambeir, X. Chen, I. De Meester, A. Haemers, K. Augustyns, and P. Van der Veken. 2011. Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal? Journal of Medicinal Chemistry American Chemical Society: 54: 5737–5746. doi:10.1021/jm200383j.
18. Yu, D.M.T., X.M. Wang, G.W. McCaughan, and M.D. Gorrell. 2006. Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. The FEBS Journal 273: 2447–2460. doi:10.1111/j.1742-4658.2006.05253.x.
19. Yao, T.W., W.S. Kim, D.M.T. Yu, G. Sharbeen, G.W. McCaughan, K.Y. Choi, P. Xia, and M.D. Gorrell. 2011. A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling. Molecular Cancer Research 9. AACR: 948–59.
20. Park, J., H.M. Knott, N.A. Nadvi, C.A. Collyer, X.M. Wang, W.B. Church, and M.D. Gorrell. 2008. Reversible inactivation of human dipeptidyl peptidases 8 and 9 by oxidation. The Open Enzyme Inhibition Journal 1: 52–60. doi:10.2174/1874940200801010052.
21. Dubois, V., C. Van Ginneken, H. De Cock, A.-M. Lambeir, P. Van der Veken, K. Augustyns, X. Chen, S. Scharpé, and I. De Meester. 2009. Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society 57: 531–541. doi:10.1369/jhc.2009.952739.
22. Lu, C., J.U. Tilan, L. Everhart, M. Czarnecka, S.J. Soldin, D.R. Mendu, D. Jeha, J. Hanafy, C.K. Lee, J. Sun, E. Izycka-Swieszewska, J.A. Toretsky, and J. Kitlinska. 2011. Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy. The Journal of Biological Chemistry 286: 27494–27505. doi:10.1074/jbc.M111.224089.
23. Pilla, E., U. Möller, G. Sauer, F. Mattiroli, F. Melchior, and R. Geiss-Friedlander. 2012. A novel SUMO1-specific interacting motif in dipeptidyl peptidase 9 (DPP9) that is important for enzymatic regulation. The Journal of Biological Chemistry 287: 44320–44329. doi:10.1074/jbc.M112.397224.
24. Schade, J., M. Stephan, A. Schmiedl, L. Wagner, A.J. Niestroj, H.-U. Demuth, N. Frerker, C. Klemann, K.A. Raber, R. Pabst, and S. von Hörsten. 2008. Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. The Journal of Histochemistry and Cytochemistry 56: 147–155. doi:10.1369/jhc.7A7319.2007.
25. Yazbeck, R., M.L. Sulda, G.S. Howarth, A. Bleich, K. Raber, S. von Hörsten, J.J. Holst, and C.A. Abbott. 2010. Dipeptidyl peptidase expression during experimental colitis in mice. Inflammatory Bowel Diseases 16: 1340–1351. doi:10.1002/ibd.21241.
26. Röhnert, P., W. Schmidt, P. Emmerlich, A. Goihl, S. Wrenger, U. Bank, K. Nordhoff, M. Täger, S. Ansorge, D. Reinhold, and F. Striggow. 2012. Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. Journal of Neuroinflammation 9: 44–59. doi:10.1186/1742-2094-9-44.
27. Chowdhury, S., Y. Chen, T.-W. Yao, K. Ajami, X.M. Wang, Y. Popov, D. Schuppan, P. Bertolino, G.W. McCaughan, D.M. Yu, and M.D. Gorrell. 2013. Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver. World Journal of Gastroenterology 19: 2883–2893. doi:10.3748/wjg.v19.i19.2883.
28. Matheeussen, V., Y. Waumans, W. Martinet, S. Van Goethem, P. Van der Veken, S. Scharpé, K. Augustyns, G.R.Y. De Meyer, and I. De Meester. 2013. Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. Basic Research in Cardiology 108: 350–364. doi:10.1007/s00395-013-0350-4.
29. Matsubara, J., S. Sugiyama, K. Sugamura, T. Nakamura, Y. Fujiwara, E. Akiyama, H. Kurokawa, T. Nozaki, K. Ohba, M. Konishi, H. Maeda, Y. Izumiya, K. Kaikita, H. Sumida, H. Jinnouchi, K. Matsui, S. Kim-Mitsuyama, M. Takeya, and H. Ogawa. 2012. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Journal of the American College of Cardiology 59: 265–276. doi:10.1016/j.jacc.2011.07.053.
30. Scirica, B.M., D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, P. Ohman, R. Frederich, S.D. Wiviott, E.B. Hoffman, M.A. Cavender, J.A. Udell, N.R. Desai, O. Mosenzon, D.K. McGuire, K.K. Ray, L.A. Leiter, and I. Raz. 2013. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England Journal of Medicine 369: 1317–1326. doi:10.1056/NEJMoa1307684.
31. Monami, M., I. Dicembrini, and E. Mannucci. 2014. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutrition, Metabolism, and Cardiovascular Diseases 24: 689–697. doi:10.1016/j.numecd.2014.01.017.
32. Getz, G.S., and C.A. Reardon. 2012. Animal models of atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 32: 1104–1115. doi:10.1161/ATVBAHA.111.237693.
33. Francke, A., J. Herold, S. Weinert, R.H. Strasser, and R.C. Braun-Dullaeus. 2011. Generation of mature murine monocytes from heterogeneous bone marrow and description of their properties. The Journal of Histochemistry and Cytochemistry 59: 813–825. doi:10.1369/0022155411416007.
34. Kim, D., L. Wang, M. Beconi, G.J. Eiermann, M.H. Fisher, H. He, G.J. Hickey, J.E. Kowalchick, B. Leiting, K. Lyons, F. Marsilio, M.E. McCann, R.A. Patel, A. Petrov, G. Scapin, S.B. Patel, R.S. Roy, J.K. Wu, M.J. Wyvratt, B.B. Zhang, L. Zhu, N.A. Thornberry, and A.E. Weber. 2005. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry 48: 141–151. doi:10.1021/jm0493156.
35. Wu, J.-J., H.-K. Tang, T.-K. Yeh, C.-M. Chen, H.-S. Shy, Y.-R. Chu, C.-H. Chien, T.-Y. Tsai, Y.-C. Huang, Y.-L. Huang, C.-H. Huang, H.-Y. Tseng, W.-T. Jiaang, Y.-S. Chao, and X. Chen. 2009. Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. Biochemical Pharmacology 78: 203–210. doi:10.1016/j.bcp.2009.03.032.
36. Matheeussen, V., A.-M. Lambeir, W. Jungraithmayr, N. Gomez, K. Mc Entee, P. Van der Veken, S. Scharpé, and I. De Meester. 2011. Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. Clinica chimica acta; international journal of clinical chemistry 413: 456–62. doi:10.1016/j.cca.2011.10.031 Elsevier B.V.
37. Bjelke, J.R., J. Christensen, P.F. Nielsen, S. Branner, A.B. Kanstrup, N. Wagtmann, and H.B. Rasmussen. 2006. Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. The Biochemical Journal 396: 391–399. doi:10.1042/BJ20060079.
38. Bryan, N.S., and M.B. Grisham. 2008. Methods to detect nitric oxide and its metabolites in biological samples. Free Radical Biology and Medicine 43: 645–657.
39. Ta, N.N., C.A. Schuyler, Y. Li, M.F. Lopes-Virella, and Y. Huang. 2011. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. Journal of Cardiovascular Pharmacology 58: 157–166. doi:10.1097/FJC.0b013e31821e5626.
40. Shah, Z., T. Kampfrath, J.A. Deiuliis, J. Zhong, C. Pineda, Z. Ying, X. Xu, B. Lu, S. Moffatt-Bruce, R. Durairaj, Q. Sun, G. Mihai, A. Maiseyeu, and S. Rajagopalan. 2011. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124: 2338–2349. doi:10.1161/CIRCULATIONAHA.111.041418.
41. Terasaki, M., M. Nagashima, T. Watanabe, K. Nohtomi, Y. Mori, A. Miyazaki, and T. Hirano. 2012. Effects of p KF275–055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metabolism 61: 974–977. doi:10.1016/j.metabol.2011.11.011.
42. Terasaki, M., M. Nagashima, K. Nohtomi, K. Kohashi, M. Tomoyasu, K. Sinmura, Y. Nogi, Y. Katayama, K. Sato, F. Itoh, T. Watanabe, and T. Hirano. 2013. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin’s actions in nondiabetic and diabetic apolipoprotein E-null mice. PLoS One 8, e70933. doi:10.1371/journal.pone.0070933.
43. Ervinna, N., T. Mita, E. Yasunari, K. Azuma, R. Tanaka, S. Fujimura, D. Sukmawati, T. Nomiyama, A. Kanazawa, R. Kawamori, Y. Fujitani, and H. Watada. 2013. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 154: 1260–1270. doi:10.1210/en.2012-1855.
44. Zhong, J., X. Rao, J. Deiuliis, Z. Braunstein, V. Narula, J. Hazey, D. Mikami, B. Needleman, A.R. Satoskar, and S. Rajagopalan. 2013. A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation. Diabetes 62: 149–157. doi:10.2337/db12-0230.
45. Barbieri, M., M.R. Rizzo, R. Marfella, V. Boccardi, A. Esposito, A. Pansini, and G. Paolisso. 2013. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 227: 349–54. doi:10.1016/j.atherosclerosis.2012.12.018 Elsevier Ltd.
46. Spagnuolo, P. A, R. Hurren, M. Gronda, N. MacLean, A. Datti, A. Basheer, F.-H. Lin, X. Wang, J. Wrana, and A D. Schimmer. 2013. Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide’s anti-leukemic activity. Leukemia 27: 1236–44. doi:10.1038/leu.2013.9 Nature Publishing Group.
47. Guzman, M.L., R.M. Rossi, S. Neelakantan, X. Li, C.A. Corbett, D.C. Hassane, M.W. Becker, J.M. Bennett, E. Sullivan, J.L. Lachowicz, A. Vaughan, C.J. Sweeney, W. Matthews, M. Carroll, J.L. Liesveld, P.A. Crooks, and C.T. Jordan. 2007. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110: 4427–4435. doi:10.1182/blood-2007-05-090621.
48. Guzman, M.L., R.M. Rossi, L. Karnischky, X. Li, D.R. Peterson, D.S. Howard, and C.T. Jordan. 2005. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105: 4163–4169. doi:10.1182/blood-2004-10-4135.
49. Zunino, S.J., J.M. Ducore, and D.H. Storms. 2007. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells. Cancer Letters 254: 119–127. doi:10.1016/j.canlet.2007.03.002.
50. Carlisi, D., A. D’Anneo, L. Angileri, M. Lauricella, S. Emanuele, A. Santulli, R. Vento, and G. Tesoriere. 2011. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. Journal of Cellular Physiology 226: 1632–1641. doi:10.1002/jcp.22494.
51. Gopal, Y.N.V., E. Chanchorn, and M.W. Van Dyke. 2009. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Molecular Cancer Therapeutics 8: 552–562. doi:10.1158/1535-7163.MCT-08-0661.
52. Brokopp, C.E., R. Schoenauer, P. Richards, S. Bauer, C. Lohmann, M.Y. Emmert, B. Weber, S. Winnik, E. Aikawa, K. Graves, M. Genoni, P. Vogt, T.F. Lüscher, C. Renner, S.P. Hoerstrup, and C.M. Matter. 2011. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. European Heart Journal 32: 2713–2722. doi:10.1093/eurheartj/ehq519.
53. Waumans, Y., L. Baerts, K. Kehoe, A.-M. Lambeir, and I. De Meester. 2015. The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Frontiers in Immunology 6. doi:10.3389/fimmu.2015.00387 Frontiers.